What is Lavior?
Lavior is dedicated to providing a comprehensive suite of treatments for diabetic wounds and skin conditions, drawing upon 15 years of dedicated research and medical expertise. The company's innovative product line is formulated using the natural healing properties of the Inula Viscosa AGS RIED species, offering botanical-based solutions for chronic dermatological issues. Lavior's mission is to prevent amputations and enhance skin health globally through its scientifically validated, pure botanical healing products. Following a recent rebranding, the company continues its commitment to science-powered natural healing.
How much funding has Lavior raised?
Lavior has raised a total of $15K across 3 funding rounds:
Multiple Rounds
$15K
Debt (2024): $5K, investors not publicly disclosed
Debt (2024): $5K led by First Internet Bancorp
Debt (2024): $5K, investors not publicly disclosed
What's next for Lavior?
As Lavior operates within the Series A/B growth stage, the recent moderate growth capital is likely to be strategically deployed to scale its operations, enhance its product development pipeline, and expand its market reach. This strategic investment will probably focus on further clinical validation, broader distribution channels, and potentially new therapeutic applications for its unique botanical formulations. The company's emphasis on preventing amputations and improving skin health through natural, science-backed methods suggests a continued focus on addressing unmet needs in the diabetic care market.
See full Lavior company page
